Inozyme Pharma, Inc. (INZY) Share-based Payment Arrangement, Expense USD 2019 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Inozyme Pharma, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2019 to 2024.
  • Inozyme Pharma, Inc. Share-based Payment Arrangement, Expense for the quarter ending March 31, 2024 was $1.69 M, a 19.2% decline year-over-year.
  • Inozyme Pharma, Inc. Share-based Payment Arrangement, Expense for the twelve months ending March 31, 2024 was $6.6 M, a 17.9% decline year-over-year.
  • Inozyme Pharma, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $7 M, a 9.09% decline from 2022.
  • Inozyme Pharma, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $7.7 M, a 6.94% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $6.6 M $1.69 M -$401 K -19.2% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 $7 M $1.64 M -$278 K -14.5% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-12
Q3 2023 $7.28 M $1.67 M -$177 K -9.57% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-07
Q2 2023 $7.46 M $1.6 M -$585 K -26.8% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-08
Q1 2023 $8.04 M $2.09 M +$340 K +19.4% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 $7.7 M $1.91 M -$144 K -7% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-12
Q3 2022 $7.84 M $1.85 M +$97 K +5.54% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 $7.75 M $2.19 M +$372 K +20.5% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $7.38 M $1.75 M +$175 K +11.1% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 $7.2 M $2.06 M Oct 1, 2021 Dec 31, 2021 10-K 2023-03-22
Q3 2021 $1.75 M +$966 K +123% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 $1.81 M +$1.69 M +1411% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-15
Q1 2021 $1.58 M +$1.45 M +1122% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q3 2020 $786 K +$679 K +635% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 $120 K +$80 K +200% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-11
Q1 2020 $129 K Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-12
Q3 2019 $107 K Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 $40 K Apr 1, 2019 Jun 30, 2019 10-Q 2020-09-03
* An asterisk sign (*) next to the value indicates that the value is likely invalid.